Cell for Use in Immunotherapy Which Contains Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product or Fragment Thereof, Method for Producing Said Cell, and Said Nucleic Acid Construct
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/JP2012/069377, filed Jul 30, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,316,332 | Cell for Immunotherapy, Including Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product In force · Medium confidence | RIKEN | In force | Medium confidence | ||
| US 11,072,802 | Cell for Immunotherapy, Including Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product In force · Medium confidence | RIKEN | In force | Medium confidence | ||
| US 9,783,821 | Cell for Use in Immunotherapy Which Contains Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product or Fragment Thereof, Method for Producing Said Cell, and Said Nucleic Acid Construct In force · High confidence | RIKEN | In force | High confidence | ||
| Application 15/708,900 | Cell for Use in Immunotherapy Which Contains Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product or Fragment Thereof, Method for Producing Said Cell, and Said Nucleic Acid Construct Abandoned Abandoned Apr 12, 2018 | RIKEN | Abandoned | Abandoned Apr 12, 2018 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by RIKEN.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.